Search results for " drug"
Article
Methods Accelerate Biosimilar Analysis
Of the approved drugs, five are biosimilars of trastuzumab; three are biosimilars each of infliximab and adalimumab; two are biosimilars each of filgrastim, pegfilgrastim, etanercept, and bevacizumab,…
Article
Intensified Chromatography Strategies
The blockbuster drug era is over and drug manufacturers are now striving for a more diversified portfolio by targeting a greater number of monoclonal antibody (mAb) products at lower production volu…
Article
News: Cytiva Adds ELISA Kit to End-to-End HCP Monitoring Capabilities
Cytiva is pleased to announce the new Amersham HCPQuant CHO kit, a generic for detecting host cell protein impurities in drug samples produced in CHO cell lines.
Learn More
Article
The Outlook for CMO Outsourcing in 2019
Most innovator drug companies continue to retain manufacturing and development of their prospective blockbusters in-house.
The financial outlook for CMOs is solid, with growth in revenue tracki…
Article
Using Multiple Techniques in Biosimilar Analysis
Whether they are called ‘sameness’ for generic drugs, ‘comparability’ for biologics, or ‘analytical similarity’ for biosimilars, these tests are crucial for any regulatory submission, which is vital t…
Article
Optimizing Late-Stage and Commercial Cell-Culture Processes
Racher anticipates seeing greater ability to tune critical product quality attributes and greater use of material from stable, transfectant pools, or pools of clonal cell lines, for drug product devel…
Article
Making the Move to Continuous Chromatography
…number of cycles will eventually be reached for a commercialized molecule with steady demand for the drug. “The real benefit,” asserts Levison, “is overall greater productivity and improved process e…
Article
Modern Manufacturing Key to More Effective Vaccines
In an announcement of spending priorities for 2019, Gottlieb highlighted the importance of advancing manufacturing technologies for drugs and biologics, including vaccines. He noted that continuous ma…
Article
Biopharmaceutical Market in Asia: Q&A with Günter Jagschies, Strategic Customer Relations Leader, Cytiva
Asia has a complex mix of economies from low to high income with a largely varying degree of access for the population to biotherapeutic drugs on the high end of the price range as well as even to the…
Article
FDA Framework Spurs Advanced Therapies
ISCT also expects the recent approvals to spark considerable investment across all stages of drug development from fundamental research within academia to commercial manufacturing by Big Pharma and co…